IRIS
Valenti, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.222
NA - Nord America 1.879
SA - Sud America 507
EU - Europa 458
AF - Africa 67
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.139
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.799
SG - Singapore 1.306
CN - Cina 454
BR - Brasile 402
VN - Vietnam 232
IT - Italia 95
HK - Hong Kong 58
FR - Francia 50
IE - Irlanda 49
AR - Argentina 47
FI - Finlandia 45
IN - India 43
GB - Regno Unito 40
DE - Germania 36
CA - Canada 33
MX - Messico 27
EC - Ecuador 25
BD - Bangladesh 24
NG - Nigeria 19
NL - Olanda 19
RU - Federazione Russa 19
ZA - Sudafrica 16
BE - Belgio 14
IQ - Iraq 13
SE - Svezia 13
ID - Indonesia 12
JP - Giappone 12
PL - Polonia 12
ES - Italia 11
PK - Pakistan 11
TR - Turchia 10
UA - Ucraina 10
VE - Venezuela 8
CO - Colombia 7
GR - Grecia 7
PE - Perù 7
TN - Tunisia 7
DZ - Algeria 6
MY - Malesia 6
AT - Austria 5
NP - Nepal 5
UZ - Uzbekistan 5
AU - Australia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
JO - Giordania 4
KE - Kenya 4
LT - Lituania 4
MA - Marocco 4
NI - Nicaragua 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
DO - Repubblica Dominicana 3
EG - Egitto 3
JM - Giamaica 3
KZ - Kazakistan 3
PA - Panama 3
PT - Portogallo 3
SN - Senegal 3
SR - Suriname 3
AZ - Azerbaigian 2
BO - Bolivia 2
BY - Bielorussia 2
CH - Svizzera 2
CL - Cile 2
ET - Etiopia 2
HN - Honduras 2
KR - Corea 2
KW - Kuwait 2
LB - Libano 2
MT - Malta 2
OM - Oman 2
PY - Paraguay 2
QA - Qatar 2
SA - Arabia Saudita 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AG - Antigua e Barbuda 1
AL - Albania 1
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
GE - Georgia 1
GT - Guatemala 1
HT - Haiti 1
IL - Israele 1
IM - Isola di Man 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
PH - Filippine 1
PS - Palestinian Territory 1
RS - Serbia 1
SV - El Salvador 1
TG - Togo 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 5.139
Salva come PNG Salva come JPEG
Città #
Singapore 482
San Jose 278
Ashburn 260
Shanghai 166
Chandler 150
Beijing 146
The Dalles 144
Dallas 117
Ho Chi Minh City 97
Boardman 80
New York 65
Hong Kong 56
Los Angeles 55
Dublin 49
Santa Clara 46
Helsinki 45
Hanoi 38
Milan 36
São Paulo 32
Wilmington 24
San Mateo 23
Lawrence 22
Princeton 22
Benin City 19
Paris 18
Buffalo 16
Council Bluffs 16
Orem 15
Phoenix 14
Brussels 13
Amsterdam 12
Brooklyn 12
Rio de Janeiro 12
Seattle 12
Tokyo 11
Guayaquil 10
Ann Arbor 9
Chennai 9
Da Nang 9
Johannesburg 9
London 9
Mexico City 9
Montreal 9
Assago 8
Belo Horizonte 7
Charlotte 7
Chicago 7
Duncan 7
Haiphong 7
Mogi das Cruzes 7
Munich 7
Poplar 7
Salvador 7
Baghdad 6
Boston 6
Buenos Aires 6
Can Tho 6
Curitiba 6
Frankfurt am Main 6
Moscow 6
Quito 6
Atlanta 5
Dhaka 5
Falkenstein 5
Hangzhou 5
Hải Dương 5
Lima 5
New Delhi 5
Rome 5
San Francisco 5
Uberlândia 5
Warsaw 5
Amman 4
Bergamo 4
Biên Hòa 4
Bratislava 4
Brno 4
Calgary 4
Caracas 4
Caraguatatuba 4
Esbjerg 4
Feira de Santana 4
Goiânia 4
Houston 4
Kyiv 4
Las Vegas 4
Managua 4
Manchester 4
Nairobi 4
Pasadena 4
Piscataway 4
Porto Alegre 4
Quảng Ngãi 4
São Bernardo do Campo 4
Tashkent 4
Thái Bình 4
Tunis 4
Uberaba 4
Wroclaw 4
Aguascalientes 3
Totale 2.961
Salva come PNG Salva come JPEG
Nome #
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 202
Chronic Hand Eczema (CHE): A Narrative Review 112
Brodalumab: a new way to inhibit IL-17 in psoriasis 112
Rosacea-like Acute Reaction After Hyaluronic Acid Dermal Filler 111
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 98
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 92
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 91
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 88
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 83
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 83
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 78
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 72
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? 71
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks 69
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) 67
Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 66
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab 66
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 66
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital 65
Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options 64
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab 64
Noninvasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal Microscopy 64
Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021 63
Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis 63
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report 63
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 62
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 61
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) 55
Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis. A prospective cohort study 54
Early predictors of psoriatic arthritis: a delphi based consensus from Italian dermatology centers 54
Potential Role of Leptin in JAK2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study 53
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 53
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma 53
Real-life efficacy of guselkumab in patients with early psoriatic arthritis 53
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 52
Urticarial rash in autoinflammatory syndromes 52
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma 51
Bullous vasculitis associated with Streptococcus pyogenes sepsis 51
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 51
Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction 50
Multiple facial angiofibromas: A manifestation of Frank-ter Haar syndrome? 49
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab 49
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 49
Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion 48
Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis 48
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review 48
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study 48
Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real‐life Italian multicenter observational study of 250 patients 47
What Can IBD Specialists Learn from IL-23 Trials in Dermatology? 47
Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy 46
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study 45
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study 45
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience 44
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study 44
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel 44
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 44
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 44
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis) 43
Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case‐series 43
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment 43
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study 43
Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) 43
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study 43
Geometric contour variation in clinical target volume of axillary lymph nodes in breast cancer radiotherapy: an AIRO multi-institutional study 42
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience 42
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 42
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? 42
Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials 41
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals 40
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience 40
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma 40
Atypical facial pustular folliculitis by Klebsiella pneumoniae: a case report 40
Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report 40
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination 39
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study 39
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) 39
Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study 39
An updated safety review of Hidradenitis Suppurativa treatment options 38
A severe case of IgA bullous pemphigoid successfully treated with dupilumab 38
Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients 37
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report 37
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study 36
Long-Term Sequential Digital Dermoscopy of Low-Risk Patients May Not Improve Early Diagnosis of Melanoma Compared to Periodical Handheld Dermoscopy 36
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis) 36
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience 35
Methotrexate-Induced Mucositis in a Patient With Angioimmunoblastic T-cell Lymphoma 35
Connective tissue panniculitis and vitiligo in a patient with stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy 35
Long-term management of pediatric psoriasis with ixekizumab: a case report 35
Nonadherence to immune-modifying therapies during the COVID-19 pandemic: the crucial role of doctor-patient communication in avoiding drug discontinuation 34
Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience 32
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review 32
Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features 32
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study 31
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 30
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management 29
Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals 29
Safety of Interleukin Inhibitors in Patients with Plaque Psoriasis and Neoplasm: A Retrospective Study from Two Referral Centers 28
State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021 22
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series 22
Age-Related Variations in Clinical, Histological, and Genetic Characteristics in Multiple and Familial Melanomas: A Study of 333 Patients 16
Totale 5.225
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.416
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.416
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 0 11
2021/2022110 1 0 3 13 2 3 5 10 26 8 32 7
2022/2023359 55 28 25 58 33 27 0 29 55 29 20 0
2023/2024528 16 37 98 28 11 49 59 45 12 22 52 99
2024/20251.163 13 35 14 19 5 105 87 61 161 222 216 225
2025/20263.031 440 242 217 285 183 142 748 168 140 194 148 124
Totale 5.247